Prior authorization challenges are consuming your practice from the inside out. Between the hours your staff spends on hold, the fax machines still churning in 2026 and a regulatory landscape shifting faster than most practices can keep up with, the PA process has become one of the single biggest drains on provider resources in American healthcare. The good news is that a combination of legislative PA reform, CMS mandates and genuine AI-driven automation is finally creating a path forward.

With the Inflation Reduction Act reshaping the pharmacy benefit, new CMS interoperability rules demanding faster turnaround times and real automation tools going far beyond what ePA alone can deliver, providers finally have a chance to reclaim the hours, staff, and patient relationships that the PA burden has been steadily eroding.

Why Prior Authorization Challenges Are More Significant Than Ever

Prior authorization was originally designed as a cost-control mechanism. Today, it has grown into a system that touches nearly every prescription and procedure a physician orders. The consequences are felt at every level of care delivery.

The Staff Time Crisis

The MGMA's Annual Regulatory Burden Report found that 92% of surveyed medical group practices have hired or reassigned staff solely to handle the growing volume of PA requests. This isn't a small operational adjustment, it's a fundamental reallocation of clinical resources away from patient care.

The numbers are sobering. According to the American Medical Association's annual PA survey, practices complete an average of 39 prior authorizations per physician per week, with physicians and their staff spending roughly 13 hours on those requests. Meanwhile, MGMA data shows that 60% of practices need at least three employees involved in completing a single PA request, and 35% report spending upwards of 35 minutes per request.

Pro Tip: If you're tracking PA burden at your practice, don't just count submission time. Factor in the follow-up calls, peer-to-peer reviews, appeal documentation and the re-work when a denial comes back with vague reasoning. The real time investment is significantly higher than what practices initially estimate.

The Post-Authorization Burden Nobody Talks About

The prior authorization challenge doesn't end once you hit "submit." For many practices, the post-authorization workload is equally crushing. One of the top barriers for prescribers is simply getting a response from the benefit plan. Staff end up in "chase mode" tracking down faxes, making follow-up calls and navigating multiple payer portals to check on request status.

When denials come back, the process starts all over again. Appeal documentation must be gathered, peer-to-peer reviews need to be scheduled, and often the clinical team must re-engage to provide additional evidence. According to the AMA's survey data, 29% of physicians have seen PAs lead to a serious adverse event for a patient in their care.

Patient Abandonment: The Hidden Casualty

This is where prior authorization challenges cause the most lasting damage. 78% of physicians reported patients sometimes or often abandon a recommended course of treatment because of PA barriers. A 2025 KFF Health Tracking Poll confirmed this from the patient side, finding that 58% of insured adults who needed specialized care experienced a delay or denial of treatment due to prior authorization.

The burnout factor is equally troubling. According to the AMA's most recent data, 95% of physicians say PA somewhat or significantly increases burnout, and 42% of provider respondents in a Health Affairs study cited PA as a high contributor to burnout, with follow-up communications being the single biggest driver.

The reality is that PA isn't just an administrative inconvenience, it's a clinical problem. When patients walk away from treatment because the process is too slow or too confusing, outcomes suffer and downstream healthcare costs often increase.

The Regulatory PA Landscape: IRA, MFN, and CMS Reform

The PA landscape is not being shaped just by practice-level frustrations. A convergence of federal legislation and regulatory action is fundamentally changing the rules, and the urgency, around PA compliance and automation.

The Inflation Reduction Act's Impact on PA Complexity

The Inflation Reduction Act of 2022 introduced the Medicare Drug Price Negotiation Program, authorizing HHS to negotiate Maximum Fair Prices (MFPs) for high-cost, single-source drugs under Medicare. The first negotiated prices for 10 Part D drugs took effect in January 2026, with additional rounds expanding to 15 more drugs in 2027, then 15 in 2028, and 20 in 2029.

This means that for providers, the PA process is becoming more complex, not less. As Pioneer Institute analysis notes, one unintended consequence of the IRA is that payers and PBMs may increase administrative barriers, such as prior authorization and step therapy, to manage their own financial exposure as drug pricing structures shift. Formulary changes driven by MFP negotiations are likely to trigger new PA requirements for medications that previously didn't need them.

On top of this, the IRA's Part D benefit redesign, including the $2,000 annual out-of-pocket cap for beneficiaries and the elimination of the coverage gap, has shifted significant financial risk to Part D plan sponsors. When plans absorb more risk, the incentive to tighten utilization management through PA grows stronger.

The IRA is a net positive for patients' out-of-pocket costs, but it's creating real downstream pressure on providers who are already drowning in PA requirements. Practices managing Medicare patients should expect formulary volatility and prepare for an increase in PA volume tied to MFP-affected drugs.

CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F)

The CMS Interoperability and Prior Authorization Final Rule, effective January 2026, represents the most significant federal action on PA reform in years. It mandates that impacted payers, including Medicare Advantage, Medicaid, CHIP and ACA exchange plans, must meet four key requirements:

• Accelerated decision timelines: Standard PA requests must receive a decision within 7 calendar days, and expedited (urgent) requests within 72 hours, beginning January 1, 2026.
  
  

• FHIR-based API integration: Payers must adopt HL7 FHIR-based APIs for ePA, enabling real-time interoperability between payer platforms and provider EHRs, with full API go-live by January 1, 2027.
  
  

• Denial transparency: All denials must include a specific, structured reason, effective January 2026, no more vague "not medically necessary" rejections.
  
  

• Public performance reporting: Payers must publish annual PA metrics including approval rates, denial rates, and average decision times, with first reports due by March 31, 2026.

CMS estimates this rule will produce at least $16 billion in savings primarily for providers over ten years. However, one critical caveat: the rule does not currently apply to drug prior authorizations. Timelines for drug PA will continue under program-specific rules, which makes automation at the pharmacy benefit level even more important.

State-Level Legislative PA Reform

The federal push is being amplified by aggressive state-level action. According to MultiState's analysis, prior authorization reform is accelerating through multiple legislative strategies across the country:

• Gold carding programs are expanding, with Arkansas, Colorado, Louisiana, Texas, West Virginia and Wyoming all having adopted legislation. In 2025, Arkansas, Texas, and West Virginia amended their existing gold card laws to extend privileges to group practices and lengthen look-back periods.
  
  

• AI restrictions are emerging as a new frontier, with Maryland requiring patient-specific data for AI-driven PA decisions and mandating human physician oversight for adverse determinations.
  
  

• Continuity of care provisions are gaining traction, with multiple states requiring new health plans to honor prior authorizations from previous insurers for 90 days to one year.
  
  

• At the federal level, the bipartisan Improving Seniors' Timely Access to Care Act of 2025 (S.1816/H.R.3514) aims to streamline and standardize PA in Medicare Advantage.

Keep in mind: Gold carding is a great development, but most state programs don't apply to prescription drug authorizations. For medication PA, which is where many of the highest-volume, highest-frustration requests live, automation is still the most direct path to relief.

Why ePA Alone Isn't Enough

Electronic prior authorization has been a meaningful step forward. It replaced some fax-based workflows, shortened submission times and brought a measure of standardization to the request process. But if you've been using ePA tools and still feel buried in PA work, you're not alone.

The Limitations of Current ePA

While electronic prior authorization can reduce the time to PA decisions, it has not produced the expected benefits in reduced provider burden or lower cost of filling out forms. The reason is straightforward, ePA digitizes the submission step, but it doesn't address the full lifecycle of a prior authorization request.

Consider what ePA typically handles versus what it doesn't:

This is where the distinction between digitization and automation becomes critical. Digitization puts the same manual process on a screen. Automation eliminates the manual steps entirely.

What Real PA Automation Looks Like

True prior authorization automation, the kind that actually gives providers their time back, covers the entire PA lifecycle from benefit verification through determination and denial management. The Association of American Medical Colleges projects a shortfall of up to 86,000 physicians by 2036, and with commercial payers denying roughly $1 of every $10 billed, manual workflows simply won't scale.

In practice, end-to-end PA automation means:

1. Automated benefit verification: Real-time checks through electronic benefit verification (eBV) with full visibility into coverage, PA requirements, and out-of-pocket costs before the patient visit.
   
   

2. AI-powered form completion: LLM-based systems that extract relevant clinical evidence from visit notes, automatically populate payer question sets, and cite supporting documentation.
   
   

3. Multi-channel submission: Not just ePA, but intelligent routing through ePA rails, AI-managed phone calls, and AI fax, with human fallback for 100% payer coverage.
   
   

4. Proactive follow-up and status tracking: Automated determination chasing that eliminates the "chase mode" burden on staff, with real-time status updates routed back to the EHR.
   
   

5. Denial analysis and appeal generation: AI that analyzes denial reasons, cross-references clinical evidence, and generates evidence-based appeal letters for provider review and submission.

When evaluating PA automation vendors, ask specifically about their payer coverage model. Many tools only work through ePA rails, which means they fall short for payers or plans that still require fax or phone-based submissions. True 99%+ payer coverage requires multiple submission channels, including AI-managed calls and fax, with human fallback.

How Automation Aligns with Regulatory PA Compliance

The regulatory changes rolling out in 2026 and 2027 aren't just creating new compliance burdens, they're actually creating the infrastructure that makes PA automation more effective.

Faster Decision Timelines Demand Faster Submissions

With the CMS-0057-F rule mandating 72-hour urgent and 7-day standard turnaround times for payer decisions, the value equation for providers shifts dramatically. If payers are now required to respond quickly, the bottleneck moves to the provider side, specifically, how fast you can get a clean, complete, properly documented request out the door.

This is where AI-powered form completion and evidence attachment become game-changers. Instead of a staff member spending 20-35 minutes per request hunting through clinical notes and manually populating payer forms, an automated system can extract the relevant clinical evidence, pre-fill the form, and have it ready for provider review in minutes.

FHIR APIs Open the Door for End-to-End Automation

The CMS mandate for payers to adopt FHIR-based Prior Authorization APIs by January 2027 creates the technical base for real-time, automated PA transactions. For practices that adopt automation platforms built on API-native architecture, this means direct integration with payer systems, no more portal-hopping, no more manual data entry across multiple platforms.

The combination of provider-side automation (AI extraction, form filling, submission) and payer-side interoperability (FHIR APIs, standardized responses) creates a closed loop where PA requests can flow electronically from clinical documentation to payer determination with minimal human intervention.

Denial Transparency Enables Smarter Appeals

Beginning in January 2026, payers must provide specific, structured denial reasons. This is a massive improvement from the vague "not medically necessary" rejections that have historically made appeals a guessing game. With structured denial data, AI-driven automation platforms can analyze denial patterns, identify the specific clinical evidence gaps, and generate targeted appeal letters that address the exact reason for denial.

This means practices aren't just appealing faster, they're appealing smarter, with higher overturn rates and less staff time per appeal.

How Develop Health Approaches PA Automation

Develop Health takes a fundamentally different approach to prior authorization challenges. Rather than digitizing manual steps, our platform eliminates them entirely through GenAI-native automation embedded directly in provider workflows.

The platform automates benefit verification and prior authorization across the full lifecycle, from real-time BV checks and AI-powered form completion to multi-channel submission (ePA, AI fax, AI calls and human fallback for 100% payer coverage). Providers review and approve requests directly in their EHR task queue, with no app-hopping or portal switching required.

For practices dealing with the IRA's changing formulary landscape, Develop Health's automated benefit verification pulls coverage, PA requirements, and out-of-pocket estimates before the visit, giving providers and patients cost transparency at the point of prescribing. When denials occur, the platform's AI analyzes denial reasons, generates evidence-based appeal letters and handles resubmission.

The results speak for themselves: customers have seen prescription-to-approval cycle times drop from 1.5 weeks to 20 hours, an 83% reduction in PA handling times, and a 14% boost in approval rates through better qualification, improved evidence collection, and proactive denial follow-up.

Frequently Asked Questions

What are the biggest prior authorization challenges facing providers in 2026? 

The most significant prior authorization challenges include the sheer volume of requests (averaging 39 per physician per week), high staff time requirements (13 hours weekly), increasing denial rates, and the complexity introduced by IRA-driven formulary changes. The CMS Interoperability and Prior Authorization Final Rule adds compliance urgency, requiring practices to adapt to new payer decision timelines and electronic workflows.

How does the Inflation Reduction Act affect prior authorization? 

The IRA's Medicare Drug Price Negotiation Program and Part D benefit redesign are changing formulary structures, which can trigger new PA requirements for medications that previously didn't need them. As Pioneer Institute analysis notes, payers may increase administrative barriers including PA and step therapy to manage their financial exposure as MFP negotiations take effect. Providers managing Medicare patients should prepare for increased PA volume on MFP-affected drugs starting in 2026.

What is the CMS Interoperability and Prior Authorization Final Rule? 

CMS-0057-F requires impacted payers (Medicare Advantage, Medicaid, CHIP, and ACA exchange plans) to meet accelerated PA decision timelines (72 hours urgent, 7 days standard), adopt FHIR-based APIs for electronic PA by 2027, provide specific denial reasons, and publicly report PA metrics. Currently, the rule does not cover drug prior authorizations specifically, though payers may voluntarily include them.

How is AI-driven PA automation different from ePA? 

Electronic prior authorization (ePA) primarily digitizes the submission step, allowing requests to be sent electronically rather than by fax. AI-driven automation goes further by handling the entire PA lifecycle: AI-powered clinical evidence extraction, automated form completion, multi-channel submission, real-time status tracking, denial analysis, and appeal generation. Health Affairs research found that ePA alone has not meaningfully reduced provider burden, suggesting that full-lifecycle automation is needed.

What is gold carding for prior authorization? 

Gold carding is a legislative reform approach that exempts providers with high PA approval rates (typically 90%+) from PA requirements for certain services. As of 2025, at least six states have adopted gold carding legislation. However, most gold card programs do not apply to prescription drug authorizations, making automation still essential for medication PA.

How much time can PA automation save a provider practice? 

According to Health Affairs Scholar research, if PA processes could be automated and even half of the nursing staff time was refocused, it would be equivalent to adding more than 100,000 RNs to the healthcare workforce. At the practice level, end-to-end automation platforms can reduce PA handling times by 70-85%, translating to significant staff hours recovered each week.

What should providers look for in a PA automation platform? 

Prioritize platforms that offer full lifecycle coverage (not just submission), multi-channel payer connectivity (ePA plus fax plus phone with human fallback), EHR integration that minimizes workflow disruption, real-time analytics and denial pattern tracking, and compliance with emerging CMS interoperability standards. The platform should also support benefit verification at the point of prescribing to catch PA requirements proactively.